Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, Wenz P, Baden J, Barrett JC, Chaudhary R, Chen L, Chen WS, Cheng JH, Cyanam D, Dickey JS, Gupta V, Hellmann M, Helman E, Li Y, Maas J, Papin A, Patidar R, Quinn KJ, Rizvi N, Tae H, Ward C, Xie M, Zehir A, Zhao C, Dietel M, Stenzinger A, Stewart M, Allen J; TMB Harmonization Consortium. Merino DM, et al. Among authors: chen l, chen sj, chen ws. J Immunother Cancer. 2020 Mar;8(1):e000147. doi: 10.1136/jitc-2019-000147. J Immunother Cancer. 2020. PMID: 32217756 Free PMC article. Clinical Trial.
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy.
Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH. Tan KT, et al. Among authors: chen sj, chen mh. J Immunother Cancer. 2020 Mar;8(1):e000485. doi: 10.1136/jitc-2019-000485. J Immunother Cancer. 2020. PMID: 32238472 Free PMC article.
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.
Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH. Chiang NJ, et al. Among authors: chen sc, chen lt, chen sj, chen mh. Clin Cancer Res. 2022 Oct 3;28(19):4248-4257. doi: 10.1158/1078-0432.CCR-22-1152. Clin Cancer Res. 2022. PMID: 35849151 Free PMC article. Clinical Trial.
3,123 results